Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. / Stahlberg, Claudia; Pedersen, Anette Tønnes; Lynge, Elsebeth; Andersen, Zorana Jovanovic; Keiding, Niels; Hundrup, Yrsa Andersen; Obel, Erik B; Ottesen, Bent.

In: International Journal of Cancer, Vol. 109, No. 5, 2004, p. 721-7.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Stahlberg, C, Pedersen, AT, Lynge, E, Andersen, ZJ, Keiding, N, Hundrup, YA, Obel, EB & Ottesen, B 2004, 'Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe', International Journal of Cancer, vol. 109, no. 5, pp. 721-7. https://doi.org/10.1002/ijc.20016

APA

Stahlberg, C., Pedersen, A. T., Lynge, E., Andersen, Z. J., Keiding, N., Hundrup, Y. A., ... Ottesen, B. (2004). Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. International Journal of Cancer, 109(5), 721-7. https://doi.org/10.1002/ijc.20016

Vancouver

Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. International Journal of Cancer. 2004;109(5):721-7. https://doi.org/10.1002/ijc.20016

Author

Stahlberg, Claudia ; Pedersen, Anette Tønnes ; Lynge, Elsebeth ; Andersen, Zorana Jovanovic ; Keiding, Niels ; Hundrup, Yrsa Andersen ; Obel, Erik B ; Ottesen, Bent. / Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. In: International Journal of Cancer. 2004 ; Vol. 109, No. 5. pp. 721-7.

Bibtex

@article{80566ab09e2111debc73000ea68e967b,
title = "Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe",
abstract = "Epidemiologic studies have shown an increased risk of breast cancer following hormone replacement therapy (HRT). The aim of this study was to investigate whether different treatment regimens or the androgenecity of progestins influence the risk of breast cancer differently. The Danish Nurse Cohort was established in 1993, where all female nurses aged 45 years and above received a mailed questionnaire (n = 23,178). A total of 19,898 women returned the questionnaire (86{\%}). The questionnaire included information on HRT types and regimens, reproductive history and lifestyle-related factors. Breast cancer cases were ascertained using nationwide registries. The follow-up ended on 31 December 1999. Women with former cancer diagnoses, women with missing information on HRT, surgical menopause, premenopausal, as well as hysterectomized women were excluded, leaving 10,874 for analyses. Statistical analyses were performed using Cox proportional hazards model. A total of 244 women developed breast cancer during follow-up. After adjustment for confounding factors, an increased risk of breast cancer was found for the current use of estrogen only (RR = 1.96; 95{\%} CI = 1.16-3.35), for the combined use of estrogen and progestin (RR = 2.70; 95{\%} CI = 1.96-3.73) and for current users of tibolone (RR = 4.27; 95{\%} CI = 1.74-10.51) compared to the never use of HRT. In current users of combined HRT with testosterone-like progestins, the continuous combined regimens were associated with a statistically significant higher risk of breast cancer than the cyclical combined regimens (RR = 4.16, 95{\%} CI = 2.56-6.75, and RR = 1.94, 95{\%} CI = 1.26-3.00, respectively). An increased risk of breast cancer was noted with longer durations of use for the continuous combined regimens (p for trend = 0.048). The European traditional HRT regimens were associated with an increased risk of breast cancer. The highest risk was found for the use of continuous combined estrogen and progestin.",
author = "Claudia Stahlberg and Pedersen, {Anette T{\o}nnes} and Elsebeth Lynge and Andersen, {Zorana Jovanovic} and Niels Keiding and Hundrup, {Yrsa Andersen} and Obel, {Erik B} and Bent Ottesen",
note = "Keywords: Aged; Breast Neoplasms; Cohort Studies; Confidence Intervals; Denmark; Estrogens; Europe; Female; Hormone Replacement Therapy; Humans; Incidence; Middle Aged; Nurses; Odds Ratio; Progestins; Questionnaires; Randomized Controlled Trials as Topic; Registries; Risk Assessment; Risk Factors",
year = "2004",
doi = "10.1002/ijc.20016",
language = "English",
volume = "109",
pages = "721--7",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "JohnWiley & Sons, Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe

AU - Stahlberg, Claudia

AU - Pedersen, Anette Tønnes

AU - Lynge, Elsebeth

AU - Andersen, Zorana Jovanovic

AU - Keiding, Niels

AU - Hundrup, Yrsa Andersen

AU - Obel, Erik B

AU - Ottesen, Bent

N1 - Keywords: Aged; Breast Neoplasms; Cohort Studies; Confidence Intervals; Denmark; Estrogens; Europe; Female; Hormone Replacement Therapy; Humans; Incidence; Middle Aged; Nurses; Odds Ratio; Progestins; Questionnaires; Randomized Controlled Trials as Topic; Registries; Risk Assessment; Risk Factors

PY - 2004

Y1 - 2004

N2 - Epidemiologic studies have shown an increased risk of breast cancer following hormone replacement therapy (HRT). The aim of this study was to investigate whether different treatment regimens or the androgenecity of progestins influence the risk of breast cancer differently. The Danish Nurse Cohort was established in 1993, where all female nurses aged 45 years and above received a mailed questionnaire (n = 23,178). A total of 19,898 women returned the questionnaire (86%). The questionnaire included information on HRT types and regimens, reproductive history and lifestyle-related factors. Breast cancer cases were ascertained using nationwide registries. The follow-up ended on 31 December 1999. Women with former cancer diagnoses, women with missing information on HRT, surgical menopause, premenopausal, as well as hysterectomized women were excluded, leaving 10,874 for analyses. Statistical analyses were performed using Cox proportional hazards model. A total of 244 women developed breast cancer during follow-up. After adjustment for confounding factors, an increased risk of breast cancer was found for the current use of estrogen only (RR = 1.96; 95% CI = 1.16-3.35), for the combined use of estrogen and progestin (RR = 2.70; 95% CI = 1.96-3.73) and for current users of tibolone (RR = 4.27; 95% CI = 1.74-10.51) compared to the never use of HRT. In current users of combined HRT with testosterone-like progestins, the continuous combined regimens were associated with a statistically significant higher risk of breast cancer than the cyclical combined regimens (RR = 4.16, 95% CI = 2.56-6.75, and RR = 1.94, 95% CI = 1.26-3.00, respectively). An increased risk of breast cancer was noted with longer durations of use for the continuous combined regimens (p for trend = 0.048). The European traditional HRT regimens were associated with an increased risk of breast cancer. The highest risk was found for the use of continuous combined estrogen and progestin.

AB - Epidemiologic studies have shown an increased risk of breast cancer following hormone replacement therapy (HRT). The aim of this study was to investigate whether different treatment regimens or the androgenecity of progestins influence the risk of breast cancer differently. The Danish Nurse Cohort was established in 1993, where all female nurses aged 45 years and above received a mailed questionnaire (n = 23,178). A total of 19,898 women returned the questionnaire (86%). The questionnaire included information on HRT types and regimens, reproductive history and lifestyle-related factors. Breast cancer cases were ascertained using nationwide registries. The follow-up ended on 31 December 1999. Women with former cancer diagnoses, women with missing information on HRT, surgical menopause, premenopausal, as well as hysterectomized women were excluded, leaving 10,874 for analyses. Statistical analyses were performed using Cox proportional hazards model. A total of 244 women developed breast cancer during follow-up. After adjustment for confounding factors, an increased risk of breast cancer was found for the current use of estrogen only (RR = 1.96; 95% CI = 1.16-3.35), for the combined use of estrogen and progestin (RR = 2.70; 95% CI = 1.96-3.73) and for current users of tibolone (RR = 4.27; 95% CI = 1.74-10.51) compared to the never use of HRT. In current users of combined HRT with testosterone-like progestins, the continuous combined regimens were associated with a statistically significant higher risk of breast cancer than the cyclical combined regimens (RR = 4.16, 95% CI = 2.56-6.75, and RR = 1.94, 95% CI = 1.26-3.00, respectively). An increased risk of breast cancer was noted with longer durations of use for the continuous combined regimens (p for trend = 0.048). The European traditional HRT regimens were associated with an increased risk of breast cancer. The highest risk was found for the use of continuous combined estrogen and progestin.

U2 - 10.1002/ijc.20016

DO - 10.1002/ijc.20016

M3 - Journal article

C2 - 14999781

VL - 109

SP - 721

EP - 727

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 5

ER -

ID: 14336124